Biotech Daily

Tuesday July 7, 2026

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH DOWN: BOTANIX UP 14%; IMUGENE DOWN 22%**

*** IMUGENE $11m PLACEMENT**

*** OPTISCAN: FDA APPROVES INSPECTA VETERINARY MICROSCOPE**

*** ENTROPY: 'TRP-8803 PSILOCIN IMPROVEMENT IN ALL 6 BINGE EATERS'**

*** ISLAND GALIDESIVIR APPROVED FOR UGANDA EBOLA**

*** OSTEOPORE SAUDI ARABIA CRANIO-FACIAL IMPLANT APPROVAL**

*** IMAGION RENEWS SIEMENS DEAL FOR PHASE Ib/II MAGSENSE TRIAL**

*** ALTERITY, FDA CONFIRM PHASE III TRIAL DETAILS**

*** NOXOPHARM REQUESTS FDA SOF-SKN MEETING**

*** BOTANIX: EU SOFDRA PATENT**

*** ARGENT: SPLASH $8m MERCER DEBT FOR CANNEPIL LICENCE**

*** BIOXYNE BECOMES BLS**

*** ADHERIUM COMPLETES 100-TO-1 CONSOLIDATION**

*** VANGUARD BELOW 5% OF CLARITY**

*** PAINCHEK LOSES M-D PHILIP DAFFAS; ANDY HOGGAN INTERIM CEO**

*** PYC APPOINTS THOMAS ULMER CFO**

*** MEMPHASYS PAYS DIRECTOR MARJAN MIKEL $154k PA TO CONSULT**

MARKET REPORT

The Australian stock market fell 0.31 percent on Tuesday July 7, 2026, with the ASX200 down 27.1 points to 8,803.9 points. Twelve of the Biotech Daily Top 40 companies were up, 20 fell, six traded unchanged and two were untraded.

Botanix was the best, up 0.3 cents or 13.6 percent to 2.5 cents, with 59.05 million shares traded. Optiscan climbed 11.1 percent; Micro-X was up 9.1 percent; Lumos, Nova Eye and Orthocell were up more than four percent; Alcidion and Avita rose two percent or more; 4D Medical, Aroa and Resmed were up more than one percent; with Clinuvel and Polynovo up by less than one percent.

Imugene led the falls, down 3.0 cents or 22.2 percent to 10.5 cents, with 15.7 million shares traded. Proteomics lost 11.4 percent; Clarity was down 9.1 percent; Prescient and Syntara were down more than eight percent; Saluda shed 6.6 percent; Atomo was down 5.6 percent; Racura fell 4.8 percent; Artrya, Cyclopharm, Imricor and Medical Developments were down more than three percent; EBR and Telix shed more than two percent; Dimerix, Emvision, Mesoblast, Nanosonics, Neuren, Pro Medicus and Starpharma lost one percent or more; with Cochlear and CSL down less than one percent.

IMUGENE

Imugene says it has “firm commitments” to raise about $11.12 million in a placement at 9.5 cents a share for the development of azer-cel and general working capital.
Imugene said the issue price was a 17.7 percent discount to the 30-day volume weighted average price and a 29.6 percent discount to the last closing price.
The company said the placement was “strongly supported by new and existing institutional investors, including long-only global investors and a global pharmaceutical company”.
Imugene said its directors had agreed to subscribe for about $120,000 of the placement, subject to shareholder approval.
The company said the funds would be used for the continued development of azer-cel, including expansion of cohorts two and three of its ongoing phase Ib blood cancer trial, regulatory engagement and manufacturing scale-up.
Imugene said that Bell Potter Securities was lead manager and bookrunner to the placement.
Imugene fell three cents or 22.2 percent to 10.5 cents with 15.7 million shares traded.

OPTISCAN IMAGING

Optiscan says it has begun US commercialization of its Inspecta veterinary microscope after US Food and Drug Administration Centre for Veterinary Medicine approval.
Last year, Optiscan said it had developed Inspecta, a microscopic imaging device designed specifically for use on animals in veterinary medicine (BD: Jun 10, 2025).
Earlier this year, the company said it filed a regulatory dossier to the FDA Centre for Veterinary Medicine for its Inspecta microscope for veterinary imaging (BD: Mar 31, 2026).
Today, Optiscan said the successful submission allowed it to begin commercial sales activity in the US and was “a pivotal milestone in the company’s transition from a technology and product developer to a commercial enterprise”.
The company said Inspecta would be launched at the American Veterinary Medical Association meeting in Anaheim, California from July 10 to 14, giving it “direct exposure to a wide sub-set of veterinary clinicians, specialists and practice decision-makers”.
Optiscan said the Inspecta device was the first of its “clinical devices to have a full regulatory dossier submitted to the FDA for comment prior to formal release”.
The company said by entering the veterinary market it was “extending its proprietary imaging technology beyond human healthcare into a large and expanding sector where demand for advanced diagnostics, faster decision-making and in-house clinical capability continues to grow”.
Optiscan said Inspecta was “designed to address the gap between clinical examination and laboratory-based diagnostics by delivering real-time cellular imaging within the veterinary workflow, creating opportunities for improved patient care, greater workflow efficiency and new in-house service offerings”.
Optiscan managing-director Prof Camile Farah said the commercialization of Inspecta into the US veterinary market was “a defining development milestone for the company”.
“It comes hot on the heels of our FDA CVM submission for Inspecta, and means we can now get cracking with the commercialization of this device, which is targeting a slice of the world’s largest veterinary healthcare market that is currently valued at more than US$15 billion,” Prof Farah said.
“It represents one important step in Optiscan’s transition into a commercial-stage medical technology company, and more such steps are expected to follow as we continue to progress multiple human patient studies involving our other devices,” Prof Farah said.
Optiscan was up 1.5 cents or 11.1 percent to 15 cents with 1.1 million shares traded.

ENTROPY NEURODYNAMICS (FORMERLY TRYPTAMINE THERAPEUTICS)

Entropy says the six-patient, first cohort of its phase I trial shows TRP-8803 psilocin led to a 100 percent clinically meaningful improvement for binge eating disorder.

Last month, Entropy said it had approval to dose the second cohort in its 12-patient, phase II trial of TRP-8803 intra-venous psilocin for binge eating (BD: Jun 15, 2026).

Previously, the company said that psilocin was the active psychedelic metabolite of psilocybin found in 'magic mushrooms' (BD: Jul 1, 2024).

Today, Entropy said the trial showed TRP-8803 achieved complete clinical remission in three patients, defined as no binge-eating episodes in the four weeks after treatment, as well as a meaningful improvement in 100 percent of patients, defined as a 30 percent improvement on previously recorded baseline scores.

The company said all six patients' weekly binge-eating episodes fell by 74 percent, a significant improvement in a chronic, treatment-resistant population, with anxiety and depression scores decreasing by about 60 percent and "life satisfaction" increasing by 63 percent across the cohort.

Entropy said the results provided what it believed was "the first reported global clinical efficacy data for precision-controlled [intra-venous]-infused psilocin and represent an important milestone in the development of psychedelic-assisted therapies".

The company said the results had "exceeded management's expectations and provide early clinical validation for Entropy's mechanistically guided precision-controlled psychedelic platform".

Entropy said it expected to begin cohort two dosing "next month", followed by results before 2027 and would "continue to pursue broader expansion into additional neuro-psychiatric indications".

Entropy was up 0.2 cents or 6.25 percent to 3.4 cents with 7.9 million shares traded.

ISLAND PHARMACEUTICALS

Island says it has "all government and regulatory approvals" for the compassionate use of galidesivir to treat infected patients in the ongoing Bundibugyo Ebola epidemic in Uganda.

Island said galidesivir would be used in the Ebola outbreak under a monitored emergency use of unregistered and investigational interventions protocol this year and was "a major opportunity to generate prospective human efficacy, safety and virological data".

The company said that the study was sponsored by the World Health Organization (W.H.O.) and the Ugandan Ministry of Health and would "provide compassionate use of investigational therapies during public health emergencies where no approved treatment options exist and conventional randomized clinical trials cannot be ethically implemented".

Island said there were "currently no approved therapeutics or vaccines for Bundibugyo Ebola or Marburg virus, creating an urgent unmet medical need and a unique opportunity for galidesivir to be evaluated in the intended disease setting while providing a new treatment option currently unavailable anywhere for Ebola patients".

The company said the study would be conducted with the Accept-Africa Consortium, the Infectious Diseases Institute at Kampala's Makerere University and the Uganda Ministry of Health following receipt of approvals from the relevant research ethics committee, Uganda's National Drug Authority and the Uganda National Council for Science and Technology.

The company said previous studies showed 100 percent survival in galidesivir-treated Ebola Zaire-infected primates compared with no survival with placebo.

Island was up 10 cents or 26.7 percent to 47.5 cents with 4.5 million shares traded.

OSTEOPORE

Osteopore says it has market approval for its 3-dimensional, bio-resorbable cranio-facial implants in Saudi Arabia, to be distributed by Zimmer Biomet.

In 2024, Osteopore said Singapore's Zimmer Biomet Holdings would sell its cranio-facial products exclusively in Europe, Africa, Asia and Australia (BD: Jul 16, 2024).

Today, the company said Saudi Arabia was within the Europe, Middle East and Africa distribution partnership, was the largest economy in the Middle East and the de-facto leader of the Gulf Cooperation Council.

Osteopore said market access in Saudi Arabia was "therefore widely viewed by global medical technology companies as a key reference point that supports market entry across the wider Gulf region".

Osteopore fell 0.1 cents or 20 percent to 0.4 cents.

IMAGION BIOSYSTEMS

Imagion says it has extended its agreement with Siemens Healthineers to assist with its phase Ib/II trial of its Magsense for breast cancer imaging agent.

In 2023, Imagion said it had extended its agreement with Australia's Siemens Healthcare Pty Ltd to work on its Magsense HER2 breast cancer imaging agent by two years and in the US (BD: Jun 28, 2023).

Last month, the company said it had US Food and Drug Administration investigational new drug approval for a 70-patient, phase Ib/II trial of Magsense human epidermal growth factor receptor-2 (HER2) agent for breast cancer imaging (BD: Jun 2, 2026).

Today, Imagion said Siemens would "continue to make in-kind contributions of expertise and limited technical support to clinical sites, working with Imagion and its clinical advisors and investigators to optimize the [magnetic resonance imaging] protocols being used in the trial".

The company said the "quantitative imaging techniques that will be deployed in the trial are expected to provide improved image quality even with lower doses of the Magsense imaging agent and reduce imaging time for improved clinical workflow".

Imagion fell 0.05 cents or 3.85 percent to 1.25 cents.

ALTERITY THERAPEUTICS

Alterity says its end-of-phase II meeting with the US Food and Drug Administration for ATH434 in multiple system atrophy confirmed the requirements for a phase III trial.

Last month, Alterity said it had "aligned" with the FDA on the design of its phase III trial of ATH434 for multiple system atrophy (BD: Jun 9, 2026).

Today, the company said the end-of-meeting minutes had confirmed the study population, treatment regimen and efficacy endpoints for its phase III trial and a path toward a potential new drug application filing.

Alterity said the phase III study was expected to enrol about 200-patients who would be randomized in a one-to-one ratio and treated with either 50mg ATH434 or placebo twice daily for 12 months.

The company said the FDA "further indicated that a single, pivotal trial plus confirmatory evidence could provide the necessary data to support an approval".

Alterity said it also planned "to offer an open label extension to participants who complete the phase III trial to continue their treatment and enhance the safety database for ATH434".

Alterity fell six cents or 8.45 percent to 65 cents.

NOXOPHARM

Noxopharm says it has formally requested a pre-investigational new drug meeting with the US Food and Drug Administration for its SOF-SKN auto-immune disease drug candidate.
Noxopharm said the meeting was “an important milestone in the drug development process” and involved a discussion of the planned clinical development pathway, along with topics such as product manufacturing, quality controls and other requirements to support an application.
The company said it expected the meeting to occur in about two months and would “help de-risk the development of SOF-SKN, the company’s auto-immune disease drug candidate, and also prepare for a future [investigational new drug] submission”.
Noxopharm managing-director Dr Olivier Laczka said while the company continued “to actively investigate prospects for a near-term pilot study in a local Australian patient population, progressing down the US regulatory pathway is a key component of our overall strategy to boost SOF-SKN’s commercial attractiveness”.
Noxopharm was up 0.1 cents or 1.1 percent to 9.5 cents.

BOTANIX PHARMACEUTICALS

Botanix says the European Patent Office has issued an intention to grant a patent protecting its sofpironium topical gel 12.45 percent, branded as Sofdra in the US.
Botanix said the patent, titled ‘Applicator and System for Pharmaceutical Preparation and Method of Use’ would protect its intellectual property until May 2039.
The company said that the patent covered commercially relevant aspects of the applicator device used with its topical gel, including features designed to support controlled administration and patient use.
Botanix was up 0.3 cents or 13.6 percent to 2.5 cents with 59.05 million shares traded.

ARGENT BIOPHARMA (FORMERLY MGC PHARMACEUTICALS)

Argent says Splash Beverage Group will pay $US5.5 million ($A7.9 million) to forgive its outstanding Mercer Street convertible notes to licence Cannepil for epilepsy.
In 2018, the then MGC (Medical Grade Cannabis) said it had Australian Therapeutic Goods Administration authorized prescriber scheme approval for Cannepil for drug-resistant epilepsy (BD: Oct 11, 2018).
Later, the company said it had an up to $15 million drawdown facility with the New York-based Mercer Street Global Opportunity Fund LLC, with $2.25 million to be received upfront (BD: Sep 10, 2020).
Today, Argent said under the agreement with the Fort Lauderdale, Florida-based Splash Beverage it would receive 15 percent royalties on all net revenues generated from future sales of Cannepil and retain 100 percent intellectual property ownership.
The company said the transaction was “a significant commercial and corporate milestone for Argent, providing up-front consideration of $US5.5 million for the global licencing rights to Cannepil while materially strengthening the company’s balance sheet”.
Argent said that on completion, the transaction would “fully eliminate the company’s principal secured liability from its balance sheet and release all associated security interests granted in connection with the Mercer facility”.
The company said the Mercer facility would “be closed with a nil balance as a result".
Argent said it would continue to manufacture Cannepil to service increasing order sizes, providing Argent ongoing commercial participation in the product’s future growth.
Argent was up 3.7 cents or 105.7 percent to 7.2 cents with 19.5 million shares traded.

BLS PHARMACEUTICALS (FORMERLY BIOXYNE)

BLS Pharmaceuticals began trading under the ticker code ‘BLS’ from today following its change of company name from Bioxyne.
Last month, Bioxyne said its extraordinary general meeting had overwhelmingly approved both its change of company name to ‘BLS Pharmaceuticals’ and a 10-to-one consolidation (BD: Jun 22, 2026).
BLS was unchanged at a post-consolidation 93 cents.

ADHERIUM

Adherium says it has completed its 100-to-one capital consolidation and has 54,887,674 shares on issue.
Last month, Adherium said its extraordinary general meeting had passed all resolutions overwhelmingly, with 98.72 percent in favor of the 100-to-one share consolidation (BD: Jun 22, 2026).
Adherium was up half a cent or 3.3 percent to 15.5 cents.

CLARITY PHARMACEUTICALS

Philadelphia, Pennsylvania’s Vanguard Group says it has ceased its substantial shareholding in Clarity and retains about 4.751 percent of the company.
Vanguard said that between May 15 and June 30, 2026 it bought shares at prices ranging from $2.10 to $3.18 a share and sold shares at prices between $2.05 and $3.44 a share.
Clarity fell 24 cents or 9.1 percent to $2.39 with six million shares traded.

PAINCHEK

Painchek says under “a planned transition” Philip Daffas will cease as managing-director, effective immediately, with Andy Hoggan to act as interim chief executive officer.
Painchek said “the process to appoint a new [chief executive officer] is progressing” and expected to announce a replacement “in due course”.
The company said chief operating officer Andy Hoggan would transition to interim chief executive officer and had “the full support of the board”.
Painchek said the planned transition would support its “financial year 2027 strategy following [US Food and Drug Administration] de novo clearance”.
The company said the board and Mr Daffas had “agreed that now is the right time for a change in leadership to accelerate Painchek’s development of the US market”.
Painchek was up 1.5 cents or 15 percent to 11.5 cents.

PYC THERAPEUTICS

PYC says it has appointed Thomas Ulmer as its chief financial officer.
PYC said Mr Ulmer had 20 years of biotechnology, pharmaceuticals and healthcare experience, had been chief financial officer of Cell Therapies Pty Ltd and Immatics NV, chief executive officer of PKG Health and worked for Allergopharma and Merck Group.
The company said Mr Ulmer held a Master of Business Administration from Giessen, Germany’s Justus Liebig University.
PYC fell two cents or 1.3 percent to $1.535 with 928,418 shares traded.

MEMPHASYS

Memphasys says it will pay director Marjan Mikel $12,833 a month ($154,000 a year) to provide “strategic advisory services including corporate and commercial strategy”.
Memphasys said the agreement with Vitasora managing-director Mr Mikel reflected “his increased involvement in the company’s operational and business development activities”.
The company said the deal had a 12-month term and either part could end the agreement with three months written notice.
Memphasys fell 0.05 cents or 6.7 percent to 0.7 cents with 2.2 million shares traded.